Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992315 | 1.00 | GRM5 (0.45) | GRM5CNR2EPHX2LMNATP53 | |
| SCHEMBL990130 | 0.90 | GRM5 (0.47) | GRM5 | |
| SCHEMBL3373104 | 0.85 | GRM5 (0.46) | GRM5CNR2L3MBTL1IDO1NPC1 | |
| SCHEMBL992597 | 0.84 | GRM5 (0.46) | GRM5LMNAMAPTNPC1RAB9A | |
| SCHEMBL991485 | 0.84 | GRM5 (0.46) | GRM5LMNAMAPTNPC1RAB9A | |
| SCHEMBL990991 | 0.84 | GRM5 (0.48) | GRM5EPHX2 | |
| SCHEMBL990891 | 0.83 | GRM5 (0.46) | GRM5EPHX2LMNAL3MBTL1NPC1 | |
| SCHEMBL990723 | 0.83 | GRM5 (0.46) | GRM5EPHX2LMNAL3MBTL1NPC1 | |
| SCHEMBL2841216 | 0.81 | GRM5 (0.43) | GRM5 | |
| SCHEMBL2838365 | 0.81 | GRM5 (0.43) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011137206-A1 | PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS) | NOVARTIS AG (CH) | 2011-11-03 | — | — | WO | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |